HIF‐PHIs are an emerging new class of agents under investigation for the treatment of anemia associated with chronic kidney disease (CKD) and work by stimulating erythropoiesis through inhibition of HIF‐prolyl hydroxylase domain enzymes (PHD1, PHD2, PHD3). This evidence concerns the gene EGLN3 and chronic kidney disease.